Mainstream

Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs

Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs

Post ContentxeneRead More

You might also be interested in reading U.S. Treasury Department Starts Work on GENIUS, Gathering Views on Illicit Activity.

August 12, 2025
In Mainstream